With so many Western firms either expanding operations in China or looking to invest in that country's emerging biotech market, we sought the insights of someone with an insider's view of that market. This week, BioCommerce Week interviewed Matthew Chervenak, CEO of General Biologic, a Shanghai-based consultancy with 10 employees, about the opportunities and challenges companies face when they enter the Chinese market. Chervenak started the business about three years ago after working as both a scientist and as a strategy consultant in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.